EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Maternal–foetal immune rejection: parallels between placental CHI and allograft rejection †

Panicos Shangaris iD, María Teresa Martín Monreal iD

The Journal of Pathology · 2025

DOI: 10.1002/path.6459 ↗

At a glance

Übersichtsarbeit in The Journal of Pathology, 2025. Written by Panicos Shangaris and 1 co-authors. Institution: Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK. Major MEDLINE topics: Graft Rejection, Kidney Transplantation, Placenta Diseases, Placenta. 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: Carlsberg Foundation, Fetal Medicine Foundation, Carlsbergfondet.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Chronic histiocytic intervillositis (CHI) is a rare placental inflammatory lesion increasingly viewed through maternal–foetal immune rejection. In this invited commentary, we discuss how a recent study bolsters the paradigm that CHI represents maternal immune rejection of the semi‐allogeneic foetus, analogous to antibody‐mediated rejection in organ transplantation. We highlight the shared histological and molecular features between CHI and kidney allograft rejection, including macrophage‐dominated inflammation, complement activation, and interferon‐gamma‐driven gene expression signatures and explore the implications of this common pathogenesis for clinical practice. Recognising CHI as an alloimmune process opens new avenues for early prediction, diagnosis, and intervention. We particularly emphasise the need for early identification of CHI, even in a first pregnancy, where no prior obstetric history exists to raise suspicion. Finally, we outline how transplant immunotherapy principles (e.g. immunosuppression and immune modulation) could transform the management of CHI, and we call for forward‐looking research that bridges immune pathology, maternal–foetal medicine, and translational therapeutics to improve pregnancy outcomes. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Graft RejectionKidney TransplantationPlacenta DiseasesPlacentaChorionic VilliMaternal-Fetal ExchangeHumansPregnancyFemale

Author keywords

antibody‐mediated rejectionchronic histiocytic intervillositisimmune toleranceimmunotherapymaternal–foetal rejectionplacentapregnancy losstransplant immunology

Authors and institutions

  • Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
  • Harris Birthright Research Centre for Foetal Medicine, King's College Hospital, London, UK.
  • Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.

ORCID profiles: Panicos Shangaris, María Teresa Martín Monreal

Funding

  • Carlsberg Foundation
  • Fetal Medicine Foundation
  • Carlsbergfondet

Cite

APA

Shangaris, P., & Martín Monreal, M. T. (2025). Maternal–foetal immune rejection: parallels between placental CHI and allograft rejection †. The Journal of Pathology. https://doi.org/10.1002/path.6459

Vancouver

Shangaris P, Martín Monreal MT. Maternal–foetal immune rejection: parallels between placental CHI and allograft rejection †. The Journal of Pathology. 2025. doi:10.1002/path.6459

BibTeX
@article{Shangaris2025,
  author = {Shangaris, Panicos and Martín Monreal, María Teresa},
  title = {Maternal–foetal immune rejection: parallels between placental CHI and allograft rejection †},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6459}
}
Start for free →